The Wall Street Journal
Patients with soft-tissue sarcoma, a rare cancer that starts in the body’s muscle or connective tissues, now have a new treatment option.
The FDA late yesterday approved GlaxoSmithKline’s drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S.
Votrient, a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer. It was approved to treat several subtypes of advanced soft-tissue sarcoma, after prior chemotherapy... Read More